Patents by Inventor James John Crawford

James John Crawford has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Macrocyclic broad spectrum antibiotics
    Patent number: 10392422
    Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
    Type: Grant
    Filed: May 19, 2015
    Date of Patent: August 27, 2019
    Assignees: RQX PHARMACEUTICALS, INC., GENENTECH, INC.
    Inventors: Tucker Curran Roberts, Peter Andrew Smith, Robert I. Higuchi, Prasuna Paraselli, Philippe Bergeron, Michael F. T. Koehler, Huiyong Hu, Jacob Bradley Schwarz, Cuong Ly, James John Crawford
  • PIPERIDINE DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7
    Publication number: 20190256518
    Abstract: The present invention concerns the identification of inhibitors of ubiquitin specific protease 7 (USP7), and methods of use thereof.
    Type: Application
    Filed: October 20, 2017
    Publication date: August 22, 2019
    Inventors: Colin O'DOWD, Tim HARRISON, Peter HEWITT, Shane ROUNTREE, Miel HUGUES, Frank BURKAMP, Linda Duncan JORDAN, Matthew HELM, Fabio BROCCATELLI, James John CRAWFORD, Lewis GAZZARD, Ingrid WERTZ, Wendy LEE
  • Macrocyclic broad spectrum antibiotics
    Patent number: 10351595
    Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
    Type: Grant
    Filed: May 19, 2015
    Date of Patent: July 16, 2019
    Assignees: RQX PHARMACEUTICALS, INC., GENENTECH, INC.
    Inventors: Tucker Curran Roberts, Peter Andrew Smith, Robert I. Higuchi, Prasuna Paraselli, Philippe Bergeron, Michael F. T. Koehler, Huiyong Hu, Jacob Bradley Schwarz, Cuong Ly, James John Crawford
  • HETEROARYL PYRIDONE AND AZA-PYRODINE COMPOUNDS
    Publication number: 20190194203
    Abstract: Heteroaryl pyridone and aza-pyridone compounds are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using heteroaryl pyridone and aza-pyridone compounds for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: June 27, 2018
    Publication date: June 27, 2019
    Applicant: Genentech, Inc.
    Inventors: James John Crawford, Daniel Fred Ortwine, BinQing Wei, Wendy B. Young
  • 2-AZABICYCLO[3.1.0]HEXAN-3-ONE DERIVATIVES AND METHODS OF USE
    Publication number: 20190119274
    Abstract: The invention relates to compounds of formula (I): wherein Q, A1, A2, A3, A5, A6, A7, A8, R4a, R4b and R5 are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
    Type: Application
    Filed: December 14, 2018
    Publication date: April 25, 2019
    Applicant: Genentech, Inc.
    Inventors: James John Crawford, Aleksandr Kolesnikov, Jianwen A. Feng
  • 2-AZABICYCLO[3.1.0]HEXAN-3-ONE DERIVATIVES AND METHODS OF USE
    Publication number: 20190119246
    Abstract: The invention relates to compounds of formula (I): wherein A1, A2, A3, A4, A5, A6, A7, A8, R4a, R4b and R5 are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
    Type: Application
    Filed: December 14, 2018
    Publication date: April 25, 2019
    Applicant: Genentech, Inc.
    Inventors: James John Crawford, Aleksandr Kolesnikov, Jianwen A. Feng
  • THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20190071404
    Abstract: Compounds of Formula (I): and salts thereof, and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: November 5, 2018
    Publication date: March 7, 2019
    Applicant: Genentech, Inc.
    Inventors: James John Crawford, Mark Zak, Terry Kellar, Yun-Xing Cheng, Wei Li, F. Anthony Romero, Paul Gibbons, Guiling Zhao, Gregory Hamilton, Simon Charles Goodacre
  • MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS
    Publication number: 20180327367
    Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
    Type: Application
    Filed: November 21, 2016
    Publication date: November 15, 2018
    Inventors: Yongsheng CHEN, Peter Andrew SMITH, Tucker Curran ROBERTS, Robert I. HIGUCHI, Prasuna PARASELLI, Michael F. T. KOEHLER, Jacob Bradley SCHWARZ, James John CRAWFORD, Cuong Q. LY, Emily J. HANAN, Huiyong HU, Zhiyong YU
  • Heteroaryl pyridone and aza-pyrodine compounds
    Patent number: 10045983
    Abstract: Heteroaryl pyridone and aza-pyridone compounds are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using heteroaryl pyridone and aza-pyridone compounds for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: August 14, 2018
    Assignee: Genentech, Inc.
    Inventors: James John Crawford, Daniel Fred Ortwine, BinQing Wei, Wendy B. Young
  • HETEROARYL PYRIDONE AND AZA-PYRODINE COMPOUNDS
    Publication number: 20180071286
    Abstract: Heteroaryl pyridone and aza-pyridone compounds are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using heteroaryl pyridone and aza-pyridone compounds for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: August 31, 2017
    Publication date: March 15, 2018
    Applicant: Genentech, Inc.
    Inventors: James John Crawford, Daniel Fred Ortwine, BinQing Wei, Wendy B. Young
  • Heteroaryl pyridone and aza-pyrodine compounds
    Patent number: 9782405
    Abstract: Heteroaryl pyridone and aza-pyridone compounds are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using heteroaryl pyridone and aza-pyridone compounds for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: October 10, 2017
    Assignee: Genentech, Inc.
    Inventors: James John Crawford, Daniel Fred Ortwine, BinQing Wei, Wendy B. Young
  • HETEROARYL PYRIDONE AND AZA-PYRODINE COMPOUNDS
    Publication number: 20160228432
    Abstract: Heteroaryl pyridone and aza-pyridone compounds are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using heteroaryl pyridone and aza-pyridone compounds for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: November 17, 2015
    Publication date: August 11, 2016
    Applicant: GENENTECH, INC.
    Inventors: James John Crawford, Daniel Fred Ortwine, BinQing Wei, Wendy B. Young
  • LINEAR PEPTIDE ANTIBIOTCS
    Publication number: 20160194358
    Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. The compounds provided herein can in other embodiments overcome the resistance conferred by single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases) and in other embodiments provide for a broad spectrum of antibiotic bioactivity. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
    Type: Application
    Filed: August 14, 2014
    Publication date: July 7, 2016
    Inventors: Peter Andrew SMITH, Tucker Curran ROBERTS, Robert I. HIGUCHI, Prasuna PARASELLI, Michael F.T. KOEHLER, James John CRAWFORD
  • Heteroaryl pyridone and aza-pyridone amide compounds
    Patent number: 9326985
    Abstract: Heteroaryl pyridone and aza-pyridone amide compounds of Formula I are provided, and various substituents including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk, and for treating cancer and immune disorders such as inflammation mediated by Btk. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: May 3, 2016
    Assignee: Genentech, Inc.
    Inventors: James John Crawford, Wendy Lee, Wendy B. Young
  • Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
    Patent number: 9260415
    Abstract: Heteroaryl pyridone and aza-pyridone amide compounds with electrophilic functionality of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk, and for treating cancer and immune disorders such as inflammation mediated by Btk. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: February 16, 2016
    Assignee: Genentech, Inc.
    Inventors: James John Crawford, BinQing Wei, Wendy B. Young
  • Heteroaryl pyridone and aza-pyridone compounds
    Patent number: 9238655
    Abstract: Heteroaryl pyridone and aza-pyridone compounds are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using heteroaryl pyridone and aza-pyridone compounds for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: January 19, 2016
    Assignee: Genentech, Inc.
    Inventors: James John Crawford, Daniel Fred Ortwine, BinQing Wei, Wendy B. Young
  • Alkylated piperazine compounds
    Patent number: 9115152
    Abstract: Alkylated piperazine compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating cancer mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of cancer in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: August 25, 2015
    Assignee: GENENTECH, INC.
    Inventors: James John Crawford, Wendy B. Young
  • HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS WITH ELECTROPHILIC FUNCTIONALITY
    Publication number: 20150158846
    Abstract: Heteroaryl pyridone and aza-pyridone amide compounds with electrophilic functionality of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk, and for treating cancer and immune disorders such as inflammation mediated by Btk. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: December 4, 2014
    Publication date: June 11, 2015
    Applicant: Genentech, Inc.
    Inventors: James John Crawford, BinQing Wei, Wendy B. Young
  • ALKYLATED PIPERAZINE COMPOUNDS
    Publication number: 20150094302
    Abstract: Alkylated piperazine compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating cancer mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of cancer in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: December 11, 2014
    Publication date: April 2, 2015
    Applicant: Genentech, Inc.
    Inventors: James John Crawford, Wendy B. Young
  • Alkylated piperazine compounds
    Patent number: 8946213
    Abstract: Alkylated piperazine compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating cancer mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of cancer in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: April 7, 2014
    Date of Patent: February 3, 2015
    Assignee: Genentech, Inc.
    Inventors: James John Crawford, Wendy B. Young